The Competition and Markets Authority’s Subsidy Advice Unit (SAU) has published a report evaluating the proposed Life Sciences Large Investment Portfolio (LSLIP) scheme under section 52 of the Subsidy Control Act 2022 (SCA 2022), following a request from the Office for Life Sciences (OLS). The scheme (expected to run from October 2025–March 2030) proposes to provide subsidies through direct grants to companies investing over £250m in UK-based life sciences manufacturing or research and development (R&D), with an estimated budget of up to £570m and maximum individual grants of £130m. To qualify for the LSLIP scheme, companies must be UK-registered, wholly private-sector businesses operating in the relevant sectors. Eligible companies must demonstrate a planned investment portfolio of £250m or more over three years in UK life sciences manufacturing or R&D, with at least one eligible UK project commencing within 12 months. Companies must also provide three years of audited accounts and offer financial guarantees for any grants secured, while demonstrating a proven track record of successfully developing or manufacturing medicines or medical devices.